Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.14, $0.04 better than the analyst estimate of $0.10. Revenue for the quarter came in at $52 million versus the consensus estimate of $52.2 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.